Zhaoke Ophthalmology Limited operates as an ophthalmic pharmaceutical company in Hong Kong, Mainland China, South Korea, and internationally. The company develops Cyclosporine A ophthalmic gel for the treatment of dry eye disease (DED); RGN-259, an eye drop indicated for moderate-to-severe DED; CsA/rebamipide ophthalmic gel for anti-inflammation and tear film stabilization; and IC-265 in Phase II clinical trial for the trea